Here are the DEF 14A proxy statements from Kodiak Sciences Inc (KOD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow KOD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KOD filings page.
Kodiak Sciences Inc. is soliciting proxies for its 2026 Annual Meeting, a virtual-only event on June 2, 2026. Stockholders of record on April 6, 2026 will vote on electing three Class II directors, an advisory say-on-pay resolution, and ratifying PricewaterhouseCoopers LLP as auditor.
The proxy describes a staggered, largely independent seven-member board, with directors and related options owning 29,786,724 shares, or 43% of common stock as of March 31, 2026. Executive pay is heavily performance-based: in 2025 about 68% of CEO and 65% of CFO compensation was at risk, and both received bonuses equal to 150% of target after exceeding clinical, regulatory, pipeline and financing goals. Kodiak outlines plans to file a Biologics License Application in diabetic retinopathy, retinal vein occlusion and wet AMD in 2026 and highlights multiple Phase 3 programs and an AI-enabled retinal imaging headset.